News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
703,091 Results
Type
Article (39882)
Company Profile (248)
Press Release (662960)
Multimedia
Podcasts (53)
Webinars (13)
Section
Business (204239)
Career Advice (2009)
Deals (35439)
Drug Delivery (95)
Drug Development (81098)
Employer Resources (172)
FDA (16221)
Job Trends (14876)
News (345372)
Policy (32575)
Tag
Academia (2556)
Accelerated approval (5)
Adcomms (22)
Allergies (91)
Alliances (49527)
ALS (101)
Alzheimer's disease (1410)
Antibody-drug conjugate (ADC) (149)
Approvals (16216)
Artificial intelligence (285)
Autoimmune disease (25)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (110)
Biotechnology (175)
Bladder cancer (88)
Brain cancer (30)
Breast cancer (348)
Cancer (2682)
Cardiovascular disease (199)
Career advice (1678)
Career pathing (30)
CAR-T (176)
CDC (25)
Cell therapy (476)
Cervical cancer (21)
Clinical research (66550)
Collaboration (944)
Company closure (3)
Compensation (626)
Complete response letters (19)
COVID-19 (2614)
CRISPR (53)
C-suite (288)
Cystic fibrosis (109)
Data (2777)
Decentralized trials (2)
Denatured (19)
Depression (51)
Diabetes (299)
Diagnostics (6405)
Digital health (21)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (129)
Drug pricing (116)
Drug shortages (27)
Duchenne muscular dystrophy (114)
Earnings (87358)
Editorial (40)
Employer branding (21)
Employer resources (147)
Events (113517)
Executive appointments (817)
FDA (17734)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (853)
Gene editing (123)
Generative AI (20)
Gene therapy (353)
GLP-1 (747)
Government (4466)
Grass and pollen (4)
Guidances (179)
Healthcare (18834)
Huntington's disease (28)
IgA nephropathy (34)
Immunology and inflammation (134)
Immuno-oncology (6)
Indications (35)
Infectious disease (2767)
Inflammatory bowel disease (146)
Inflation Reduction Act (9)
Influenza (56)
Intellectual property (109)
Interviews (312)
IPO (16570)
IRA (42)
Job creations (3634)
Job search strategy (1422)
Kidney cancer (13)
Labor market (49)
Layoffs (484)
Leadership (17)
Legal (7919)
Liver cancer (77)
Lung cancer (380)
Lymphoma (193)
Machine learning (9)
Management (58)
Manufacturing (354)
MASH (84)
Medical device (13422)
Medtech (13427)
Mergers & acquisitions (19532)
Metabolic disorders (766)
Multiple sclerosis (94)
NASH (16)
Neurodegenerative disease (106)
Neuropsychiatric disorders (30)
Neuroscience (2041)
NextGen: Class of 2025 (6516)
Non-profit (4485)
Now hiring (45)
Obesity (398)
Opinion (214)
Ovarian cancer (93)
Pain (100)
Pancreatic cancer (107)
Parkinson's disease (175)
Partnered (22)
Patents (275)
Patient recruitment (136)
Peanut (48)
People (57553)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20748)
Phase II (29316)
Phase III (21815)
Pipeline (1541)
Policy (175)
Postmarket research (2563)
Preclinical (8830)
Press Release (64)
Prostate cancer (130)
Psychedelics (31)
Radiopharmaceuticals (252)
Rare diseases (431)
Real estate (5912)
Recruiting (65)
Regulatory (22463)
Reports (50)
Research institute (2324)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (45)
Schizophrenia (79)
Series A (144)
Series B (97)
Service/supplier (11)
Sickle cell disease (57)
Special edition (18)
Spinal muscular atrophy (147)
Sponsored (31)
Startups (3583)
State (2)
Stomach cancer (13)
Supply chain (71)
Tariffs (55)
The Weekly (32)
Vaccines (740)
Venture capitalists (47)
Weight loss (244)
Women's health (41)
Worklife (16)
Date
Today (135)
Last 7 days (509)
Last 30 days (2406)
Last 365 days (31730)
2025 (14985)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46539)
2018 (35019)
2017 (32111)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (719)
Alabama (58)
Alaska (7)
Arizona (241)
Arkansas (13)
Asia (38091)
Australia (6217)
California (7093)
Canada (2244)
China (625)
Colorado (301)
Connecticut (306)
Delaware (180)
Europe (81854)
Florida (1066)
Georgia (237)
Idaho (58)
Illinois (606)
India (26)
Indiana (346)
Iowa (16)
Japan (210)
Kansas (108)
Kentucky (27)
Louisiana (13)
Maine (64)
Maryland (986)
Massachusetts (5265)
Michigan (238)
Minnesota (429)
Mississippi (3)
Missouri (85)
Montana (28)
Nebraska (25)
Nevada (77)
New Hampshire (65)
New Jersey (1970)
New Mexico (28)
New York (1991)
North Carolina (1044)
North Dakota (8)
Northern California (3130)
Ohio (227)
Oklahoma (15)
Oregon (34)
Pennsylvania (1541)
Puerto Rico (16)
Rhode Island (36)
South America (1097)
South Carolina (32)
South Dakota (1)
Southern California (2648)
Tennessee (118)
Texas (1050)
United States (26307)
Utah (210)
Virginia (172)
Washington D.C. (71)
Washington State (602)
West Virginia (4)
Wisconsin (63)
703,091 Results for "visterra inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases
June 13, 2025
·
2 min read
Press Releases
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
December 17, 2024
·
1 min read
Policy
Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc., ; Otsuka Pharmaceutical, Co. Ltd. ; and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin A nephropathy.
February 16, 2024
·
7 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners
June 16, 2025
·
6 min read
Press Releases
Therma Bright Inc. Announces Share Consolidation
June 11, 2025
·
3 min read
Press Releases
Bloom Burton & Co. Inc. Announces Exercise of Satellos Bioscience Inc. Warrants
May 21, 2025
·
1 min read
Press Releases
Bionoid Pharma, Inc. Confirms Name Change to AI Maverick Intel, Inc. Following Delaware Approval
May 29, 2025
·
1 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
June 12, 2025
·
5 min read
Drug Development
New England Journal of Medicine Publishes Complete Results of Positive Phase 2 Trial of Sibeprenlimab in Treatment of Immunoglobulin A Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization, Inc. and Visterra Inc., today announced that the full results of a Phase 2 trial of sibeprenlimab (VIS649) for treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease) have been published in the New England Journal of Medicine.
November 2, 2023
·
8 min read
Press Releases
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
June 9, 2025
·
3 min read
1 of 70,310
Next
